Overview

Phase II/III of Recombinant Human Serum Albumin

Status:
Not yet recruiting

Trial end date:
2024-12-31

Target enrollment:

Participant gender:

Summary

This is a randomized, double-blind, position-controlled, parallel group phase II/III clinical study of recombinant human serum albumin (rHSA) in cirrhotic ascites patients.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Protgen Ltd